Valuation: Lexaria Corp

Market Cap 5.21M 4.58M 4.34M 3.92M 7.39M 499M 7.49M 51.96M 20M 255M 19.55M 19.12M 818M P/E 2026 *
-0.78x
P/E 2027 * -0.68x
Enterprise Value 5.21M 4.58M 4.34M 3.92M 7.39M 499M 7.49M 51.96M 20M 255M 19.55M 19.12M 818M EV / Sales 2026 *
260x
EV / Sales 2027 * 3.71x
Free-Float
96.68%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2024
Director of Finance/CFO 66 01/10/2024
President 55 15/04/2015
Director TitleAgeSince
Chairman 65 26/10/2006
Director/Board Member 72 08/07/2011
Director/Board Member 55 29/04/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%-2.58%+39.49%+113.89% 1,031B
-0.81%-3.08%+41.01%+69.09% 638B
-0.48%-1.92%+6.41%+75.41% 462B
-0.45%-2.28%+60.43%+41.00% 359B
-0.13%-4.21%+23.31%+40.33% 335B
-1.68%-0.94%+13.29%+26.21% 273B
-1.68%-2.73%-3.01%+10.16% 253B
-1.68%+2.33%+39.20%+56.03% 228B
-0.86%-1.35%+32.86%+99.28% 185B
Average -0.93%-0.36%+28.11%+59.04% 418.21B
Weighted average by Cap. -0.81%-0.35%+31.14%+70.53%

Financials

2026 *2027 *
Net sales 20K 17.61K 16.69K 15.06K 28.39K 1.92M 28.76K 200K 76.83K 980K 75.1K 73.46K 3.14M 1.4M 1.24M 1.17M 1.06M 1.99M 135M 2.02M 14.01M 5.39M 68.77M 5.27M 5.15M 220M
Net income -6.64M -5.85M -5.54M -5M -9.43M -637M -9.55M -66.27M -25.5M -325M -24.93M -24.39M -1.04B -8.95M -7.88M -7.46M -6.74M -12.7M -858M -12.87M -89.31M -34.37M -439M -33.6M -32.86M -1.41B
Net Debt - -
Logo Lexaria Corp
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Employees
-